Author of

• 25938

  +

  P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26832

    +

    P2.01-36 - Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review (ID 12796)

    16:45 - 18:00  |  Author(s): Beata Korytowsky
    • Abstract
    • Slides

    Background
    

    Clinical practice guidelines in North America for first-line (1L) treatment of advanced NSCLC (aNSCLC) include a range of systemic therapy combinations, with consideration given to patient and disease characteristics. As the aNSCLC treatment landscape evolves, it is relevant to understand which combinations are routine in clinical practice. We aimed to characterize treatment patterns in real-world (RW) practice in the US and Canada.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A systematic literature review of RW observational studies was conducted using EMBASE and MEDLINE (January 2012 to March 2018), alongside searches of conference proceedings (2015 to 2018). Two reviewers assessed eligibility and included studies that described treatment patterns among treatment-naïve patients with aNSCLC. Studies focusing exclusively on sub-populations, e.g. EGFR+ or ALK+ were excluded. Data regarding the study’s sampling frame and the frequency and type of therapies received (1L systemic regimens, other 1L treatment modalities, maintenance therapy, subsequent lines of systemic therapy) were extracted and validated.

    4c3880bb027f159e801041b1021e88e8 Result
    

    From 4600 abstracts, 18 studies met inclusion criteria (n=14 US; n=4 Canada). All studies used a retrospective design; patient sample sizes ranged from 147 to 55,189 and study periods ranged from 2000 to 2015. Six studies (n=5 US; n=1 Canada) applied a sampling frame that captured all regimens available in 1L and provided breakdowns by 1L regimen (Figure 1). Eight studies (n=8 US) applied a sampling frame restricted to a pre-defined subset of 1L regimens. Among these, five were restricted to those receiving bevacizumab-based regimens; the remaining three restricted to those on specific platinum doublet regimens. Four studies (n=1 US; n=3 Canada) provided breakdowns only by treatment modality (surgery, radiation, best supportive care or no systemic therapy).

    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The identified studies capture treatment patterns primarily in an era when immunotherapy was unavailable in the 1L setting and reflect the prevalent use of platinum doublets as the mainstay of 1L treatment.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.